文献速递艾滋病与性传播感染

HIV感染者中拉替拉韦或替诺福韦/恩曲他滨存在下利托那韦增效达芦那韦的群体药代动力学与药物遗传学及病毒学应答关系:NEAT001/ANRS143随机试验子研究

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该子研究基于NEAT001/ANRS143随机试验,在初治HIV感染者中应用非线性混合效应模型分析达芦那韦、利托那韦、替诺福韦和恩曲他滨的群体药代动力学,并评估人口学因素、基因多态性与病毒学失败的关系。结果显示达芦那韦浓度不受拉替拉韦影响,且与病毒学失败无关,所研究的基因多态性对药代动力学影响甚微。

要点

  • 拉替拉韦不影响达芦那韦或利托那韦的表观口服清除率。
  • 达芦那韦AUC0-24和C24与病毒学失败时间无显著关系。
  • 所研究基因多态性对研究药物药代动力学影响较小。

核心结论

  • 达芦那韦浓度在拉替拉韦存在下未改变,且与病毒学失败无关。
  • 所研究的多态性对研究药物药代动力学影响甚微。
  • 达芦那韦/利托那韦+拉替拉韦可能是经历NRTI相关毒性患者的合适选择。

研究设计与样本

  • NEAT001/ANRS143随机试验子研究,纳入初治HIV感染者。
  • 应用非线性混合效应模型(NONMEM v. 7.3)确定药代动力学参数并评估人口学协变量和SNP关系。
  • 达芦那韦、利托那韦、替诺福韦和恩曲他滨模型分别纳入716、720、347和361例(11%女性,83%高加索人)。

主要发现

  • 达芦那韦或替诺福韦表观口服清除率未观察到人口学或SNP显著影响。
  • 利托那韦CL/F在NR1I2 63396C>T携带者中降低23%。
  • 恩曲他滨CL/F与肌酐清除率线性相关(P<0.001)。
  • 达芦那韦AUC0-24与病毒学失败时间无显著关系[HR 2.28(95%CI 0.53-9.80),P=0.269]。
  • 达芦那韦C24与病毒学失败时间无显著关系[HR 1.82(95%CI 0.61-5.41),P=0.279]。

关键数值与推荐

  • 利托那韦CL/F在NR1I2 63396C>T携带者中降低23%。
  • 恩曲他滨CL/F与肌酐清除率线性相关(P<0.001)。

临床怎么用

  • 达芦那韦/利托那韦+拉替拉韦方案可用于经历NRTI相关毒性的患者。
  • 治疗药物监测中达芦那韦浓度与病毒学失败无明确关联,常规监测价值有限。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: NEAT001/ANRS143 demonstrated non-inferiority of once-daily darunavir/ritonavir (800/100 mg) + twice-daily raltegravir (400 mg) versus darunavir/ritonavir + tenofovir disoproxil fumarate/emtricitabine (245/200 mg once daily) in treatment-naive patients. We investigated the population pharmacokinetics of darunavir, ritonavir, tenofovir and emtricitabine and relationships with demographics, genetic polymorphisms and virological failure. METHODS: Non-linear mixed-effects models (NONMEM v. 7.3) were applied to determine pharmacokinetic parameters and assess demographic covariates and relationships with SNPs (SLCO3A1, SLCO1B1, NR1I2, NR1I3, CYP3A5*3, CYP3A4*22, ABCC2, ABCC10, ABCG2 and SCL47A1). The relationship between model-predicted darunavir AUC0-24 and C24 with time to virological failure was evaluated by Cox regression. RESULTS: Of 805 enrolled, 716, 720, 347 and 361 were included in the darunavir, ritonavir, tenofovir and emtricitabine models, respectively (11% female, 83% Caucasian). No significant effect of patient demographics or SNPs was observed for darunavir or tenofovir apparent oral clearance (CL/F); coadministration of raltegravir did not influence darunavir or ritonavir CL/F. Ritonavir CL/F decreased by 23% in NR1I2 63396C>T carriers and emtricitabine CL/F was linearly associated with creatinine clearance (P<0.001). No significant relationship was demonstrated between darunavir AUC0-24 or C24 and time to virological failure [HR (95% CI): 2.28 (0.53-9.80), P=0.269; and 1.82 (0.61-5.41), P=0.279, respectively]. CONCLUSIONS: Darunavir concentrations were unaltered in the presence of raltegravir and not associated with virological failure. Polymorphisms investigated had little impact on study-drug pharmacokinetics. Darunavir/ritonavir + raltegravir may be an appropriate option for patients experiencing NRTI-associated toxicity.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Dickinson L, Gurjar R, Stöhr W, et al. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. J Antimicrob Chemother. 2020. PMID: 31754703. doi:10.1093/jac/dkz479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。